Subscribe to our News Updates & Alerts
ASX AGN:
A$
Home
About
Company Overview
Our Mission
Board
Management
Clinical Advisory Committee
Partnerships
Investors
Investor Hub
Share Information
Announcements
Reports
Presentations
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
2023
22 Sep 2023
Perth developed drug, ARG-007, shows encouraging signs to prevent impacts of traumatic brain injuries
Reference:
The West Australian
06 Sep 2023
Strokes cost the Australian economy billions, but these biotech players could change that
Reference:
The Australian
06 Sep 2023
90 Seconds With… Dr Liz Dallimore, Argenica Therapeutics (ASX:AGN)
Reference:
Stockhead
05 Sep 2023
The right medical combination
Reference:
Market Open
23 Oct 2023
$AGN Argenica Therapeutics is developing drugs which focus on preventing brain injury
Reference:
The Market Bull
18 Oct 2023
Groundbreaking: This drug could be ‘significantly effective’ at treating brain damage in newborns
Reference:
Stockhead
05 Oct 2023
Perth stroke treatment hits phase 2
Reference:
Medical Forum
04 Oct 2023
Argenica Therapeutics greenlit to launch Phase II trials into stroke treatment
Reference:
Clinical Trials Arena
06 Nov 2023
Stroke Trial – Jenny Seaton
Reference:
Curtin FM
03 Nov 2023
Data shows Argenica’s drug inhibits another main cause of Alzheimer’s disease
Reference:
Stockhead
Subscribe to our mailing list to stay up to date with Argenica Therapeutics
Home
About
Company Overview
Our Mission
Board
Management
Clinical Advisory Committee
Partnerships
Investors
Investor Hub
Share Information
Announcements
Reports
Presentations
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
Privacy Policy
Terms & Conditions
